Novartis Ag (NVSEF) EPS (Weighted Average and Diluted) (2009 - 2025)

Novartis Ag has disclosed EPS (Weighted Average and Diluted) across 15 years of filings, most recently posting $1.2 billion for Q2 2025.

• EPS (Weighted Average and Diluted) for Q2 2025 came in at $1.2 billion, down 12.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (down 53.77% YoY), and the FY2025 annual result was $2.0 billion, down 3.86% from the prior year.
• EPS (Weighted Average and Diluted) came in at $1.2 billion for Q2 2025 at Novartis Ag, down from $1.2 billion in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.3 billion in Q2 2024 to a low of $0.92 in Q2 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is $142.6 million (2023), against an average of $405.8 million.
• Across the five-year window, EPS (Weighted Average and Diluted) plunged 100.0% in 2021 and surged 4569454203.66% in 2023, its largest moves.
• Novartis Ag's EPS (Weighted Average and Diluted) stood at $560.3 million in 2021, then slumped by 90.2% to $54.9 million in 2022, then declined by 15.6% to $46.3 million in 2023, then jumped by 2462.27% to $1.2 billion in 2024, then decreased by 1.65% to $1.2 billion in 2025.
• The last three EPS (Weighted Average and Diluted) figures came in at $1.2 billion (Q2 2025), $1.2 billion (Q4 2024), and $1.3 billion (Q2 2024), per Business Quant data.